PAR-25-106 Cancer Nanotechnology R01 Eligibility Guide
Updated 8 official sources
Quick Answer: PAR-25-106 was an NCI R01 for cancer nanotechnology projects focused on mechanistic knowledge and nanoscale approaches. As of June 16, 2026, NIH marks it expired.
Full answer and how we checked it
It used a 300 nm nanoscale frame, did not allow clinical trials, and remains useful only as route intelligence for teams comparing active NCI paths such as PAR-25-336, PAR-25-338, PAR-25-153, parent R01, or SBIR/STTR.
Who this is for: Cancer nanotechnology researchers, oncology engineering teams, nanoparticle labs, diagnostic-device teams, therapeutic-delivery researchers, and sponsored-research offices reviewing prior PAR-25-106 fit or planning future NCI routes.
Data note: This guide uses NIH PAR-25-106 (opens in a new tab), NCI Cancer Nanotechnology Alliance information (opens in a new tab), NCI funding announcements (opens in a new tab), NIH PAR-25-153 (opens in a new tab), NIH PAR-25-336 (opens in a new tab), NIH PAR-25-338 (opens in a new tab), Grants.gov listing 357274 (opens in a new tab), and Grantsights award-data signals checked on June 19, 2026.
In this guide
- Source Check
- 6 PAR-25-106 Eligibility Stop Checks
- 5 Funding, Timing, and Mechanism Rules
- 5 Route Choices After Expiration
- What NIH Doesn't Tell You
- 7 Evidence Assets That Made This R01 Stronger
- 7 Source-Backed Search Questions
- 21-Day Route-Intelligence Plan
- 6 Reviewer-Risk Signals to Fix
- 5 Signals to Check Before Choosing a Route
- 5 Applicant Types and Best Next Move
- 8 Applicant Memo Lines To Include
- 6 Common Route Mistakes
- 9 Review-Ready Proof Points
- Sources
According to NIH PAR-25-106 (opens in a new tab), the route supported NCI R01 projects generating mechanistic knowledge tied to nanotechnology-based cancer interventions, diagnostics, and oncology problems.
Expired NOFO pages still matter because applicants use them to understand prior programs, compare reissues, and decide what route to watch next.
Use this guide with the live NCI Cancer Nanotechnology R01 program record. Then compare NIH grants complete guide, NIH R01 R21 R03 K awards comparison, NCI Assay Screening R01 guide, Academic-Industrial Translation R01 guide, and the Grantsights grant database.
Source Check
Checked June 2026.
As of June 19, 2026, NIH marks PAR-25-106 as expired. The final listed application date was May 4, 2026, and the expiration date was May 5, 2026.
The useful current screen is route selection. PAR-25-106 was mechanistic cancer nanotechnology, clinical trial not allowed, and built around active components at 300 nm or less plus engineered nanoscale function. Teams now need to compare active routes: PAR-25-336 for translational nanotechnology cancer interventions, PAR-25-338 for academic-industrial technology translation without a clinical trial, PAR-25-153 for assay or screening projects, parent R01 for mechanistic work that is not route-specific, and SBIR/STTR for company-led product work. The May 18, 2026 PAR-25-336 receipt date has passed, so November 16, 2026 is the next listed TTNCI date. NCI's current funding-announcement page also keeps TTNCI visible with a November 16, 2027 expiration date.
| Current source owner | What the applicant should do |
|---|---|
| NIH PAR-25-106 | Treat IRCN as expired source history, not an application path |
| NCI cancer nanotechnology pages | Use for program context, not deadline control |
| NCI funding announcements | Cross-check active NCI cancer technology routes and expiration dates before choosing a stale route |
| NIH PAR-25-336 | Compare when the project is advanced preclinical cancer nanotechnology translation |
| NIH PAR-25-338 | Compare when academic-industry technology translation is the route owner |
| NIH PAR-25-153 | Compare when the work is assay or screening centered |
Get grant deadline alerts by email
About once a week, we email a short list of open grant calls with real deadlines from different funders. It isn't limited to the programs in this guide.
No spam. Unsubscribe anytime.
6 PAR-25-106 Eligibility Stop Checks
6 stop checks decide whether a project would have fit this prior route and what to watch for in a reissue or adjacent NCI path.
| Stop check | Strong fit signal | Red flag |
|---|---|---|
| Source status | Page is used for route intelligence | Applicant assumes it is open |
| Cancer relevance | Cancer biology or oncology problem is central | Cancer link is incidental |
| Nanotech criteria | Active component is 300 nm or less | Material is not nanoscale |
| Mechanistic focus | Project explains biological interaction mechanisms | Product translation dominates |
| Trial status | No clinical trial or human intervention study | Clinical work is planned |
| Scope | R01 mechanistic project is credible | Service, manufacturing, or product launch dominates |
Don't use an expired route as an application target. Use it to understand NCI's prior priorities and compare current routes.
5 Funding, Timing, and Mechanism Rules
5 public rules should appear in the route memo. According to NIH, PAR-25-106 was an R01 clinical trial not allowed opportunity and has expired. Grantsights records the final deadline as May 4, 2026.
| Rule | Source-backed read |
|---|---|
| Funding number | PAR-25-106 |
| Mechanism | R01 research project grant |
| Clinical trial status | Not allowed |
| Source status | Expired |
| Final Grantsights deadline | May 4, 2026 |
USASpending.gov data shows about $533.3M in FY2024 obligations across 1,844 awards active that year for the connected assistance-listing family in Grantsights. That history is useful for market intelligence, but active-route selection now requires a current NOFO.
5 Route Choices After Expiration
5 route choices matter now that PAR-25-106 is expired.
| Route | Better first read when... | Why |
|---|---|---|
| Future IRCN reissue | NCI opens a successor route | Closest fit if reissued |
| Parent R01 | Mechanistic cancer nanotech work remains strong | Active route may fit |
| PAR-25-153 | Assay or screening is central | NCI screening route may fit |
| PAR-25-336 TTNCI | Nanotechnology cancer intervention is ready for advanced preclinical translation | Active NCI nanotechnology translation route may fit |
| PAR-25-338 | Academic-company technology translation is central | Partnership route may fit |
| SBIR/STTR | Company-led product work is central | Business route may fit |
The best first move is a source-status memo. It should say this exact route is closed, list the closest active options, and define the project feature that controls route choice.
What NIH Doesn't Tell You
4 hidden readiness questions still matter for teams using this route as a model.
First, NIH did not fund nanotechnology for its own sake. The project needed to explain a cancer biology or oncology problem and why nanoscale properties mattered.
Second, NIH did not make product translation the main goal. The route emphasized mechanistic understanding that could inform future nanotechnology-based cancer interventions.
Third, NIH did not allow clinical trials. Human intervention studies belonged elsewhere.
Fourth, NIH did not treat all small materials as responsive. The nanoscale criteria and engineered or modified function mattered.
Official pages state that PAR-25-106 has expired, but search results often leave applicants with a stale listing and no decision path. Grantsights adds the missing layer by pairing the prior nanoscale and clinical-trial rules with active-route comparisons, award-family context, bad-fit signals, and a 21-day route-intelligence workflow.
According to NIH, PAR-25-106 has expired. According to NCI, cancer nanotechnology remains an active research area, but the route decision now has to move through current sources. If the project is assay or screening centered, compare PAR-25-153. If it is translation of a nanotechnology intervention, compare PAR-25-336 before assuming a parent R01 is best.
According to Grants.gov, listing 357274 is the federal record tied to the expired PAR-25-106 route. According to NIH PAR-25-153, assay and screening work has a separate active R01 path, so a nanotechnology team should not treat every current cancer technology project as a parent-R01 problem.
7 Evidence Assets That Made This R01 Stronger
7 evidence assets helped a PAR-25-106-style application read as review-ready.
First, define the tumor type or cancer pathway. NIH expected applicants to focus on one or two rationally selected tumor types or pathway-based cancer groups.
Second, show the nanoscale basis. The material, device, or active component should meet the size and engineered-function expectations.
Third, explain the mechanism. The project should teach reviewers something about nanomaterial or nanodevice interactions with biological systems.
Fourth, separate mechanism from translation. A practical cancer application can motivate the work, but the R01 should not read like a product launch.
Fifth, define preclinical or model systems clearly. One university in Massachusetts testing tumor microenvironment interactions of a nanoparticle platform could specify tumor type, delivery route, readout, and mechanistic endpoint.
Sixth, handle non-responsive risks. Naturally occurring materials without engineered function, clinical trials, and AIDS/HIV-focused cancer work were outside the route.
Seventh, map current options. Since the source is expired, a user should compare active NCI, parent NIH, SBIR/STTR, and technology translation paths.
7 Source-Backed Search Questions
7 search questions should be answered clearly. The first is whether PAR-25-106 is open. It isn't. NIH marks it expired, and that should be stated before any fit advice.
The second is whether clinical trials were allowed. They weren't. Human intervention studies were outside the route.
The third is what counted as nanotechnology. NIH pointed to active components at 300 nm or less and engineered or modified materials with nanoscale properties or functions.
The fourth is whether product translation was the main purpose. The honest read is no. The route centered on mechanistic knowledge that could inform future cancer nanotechnology work.
The fifth is whether naturally occurring materials fit. NIH treated unmodified natural materials as non-responsive.
The sixth is whether users should compare active routes. Yes.
It should, as long as it is honest about status and helps users find active next steps.
21-Day Route-Intelligence Plan
21 days is enough to decide what to do after finding PAR-25-106. Days 1 through 3 should confirm source status, final deadline, and whether a reissue exists.
Days 4 through 7 should classify the project: mechanism-focused, assay/screening, academic-company translation, product development, or clinical study.
Days 8 through 12 should compare active routes: parent R01, PAR-25-153, PAR-25-338, SBIR/STTR, and any current NCI nanotechnology opportunity.
Days 13 through 16 should build the nanoscale fit memo: cancer problem, material or device criteria, mechanism, model, and endpoint.
Days 17 through 21 should prepare a program-staff question memo for the closest active route.
6 Reviewer-Risk Signals to Fix
6 risk signals remain relevant even though this source is expired. First, do not say a closed NOFO is open.
Second, do not pitch general nanotechnology without a cancer mechanism.
Third, do not ignore the nanoscale criteria.
Fourth, do not turn the project into a clinical trial.
Fifth, do not make product launch the main goal.
Sixth, do not skip active-route comparison.
5 Signals to Check Before Choosing a Route
5 signals show whether this expired route still matters for your project. Signal 1 is source status: PAR-25-106 is expired and should not be treated as an active application path.
Signal 2 is prior fit: the project should still explain the cancer problem, nanoscale function, engineered component, and mechanistic question.
Signal 3 is clinical-trial fit: this prior route did not allow clinical trials.
Signal 4 is active-route fit: compare parent R01, PAR-25-153, PAR-25-336, SBIR/STTR, and any future NCI reissue.
Signal 5 is next action: ask NCI program staff, or check the current NCI funding announcements, when the team needs project-specific route review, prior-award context, reissue timing, and topic comparison.
5 Applicant Types and Best Next Move
5 applicant types commonly land on PAR-25-106.
| Applicant type | Best next move | Why |
|---|---|---|
| Cancer nanotech PI | Check for reissue and compare parent R01 | Source is expired |
| Assay or screening team | Compare PAR-25-153 | Better active fit may exist |
| Academic-company team | Compare PAR-25-338 | Translation route may fit |
| Company-led product team | Compare SBIR/STTR | Business route may fit |
| Sponsored-project office | Flag source status | Closed routes can waste time |
The best answer is: do not draft for PAR-25-106 now. Use it to understand NCI cancer nanotechnology fit, then choose an active route.
If a page about an expired grant doesn't send users to current options, it isn't doing its job.
8 Applicant Memo Lines To Include
8 memo lines help turn an expired source into useful route intelligence. According to Grantsights data, the connected NCI assistance-listing family recorded about $533.3M in FY2024 obligations, so the topic still matters even though this exact NOFO is closed. Line 1 should state that PAR-25-106 is expired and should not be treated as an active application path.
Line 2 should name the cancer problem, tumor type, or pathway the project addresses.
Line 3 should describe the nanoscale material, device, or active component and explain how it meets the prior size and engineered-function expectations.
Line 4 should explain the mechanism being studied. The project should not only say the nanomaterial may work; it should say what biological interaction will be learned.
Line 5 should state whether the project is preclinical, model-based, diagnostic, delivery-focused, or mechanistic.
Line 6 should state why clinical trials are not part of the work.
Line 7 should name the active route the team should check next, such as parent R01, PAR-25-153, PAR-25-338, SBIR/STTR, or a future NCI reissue.
Line 8 should define what information is still missing before route selection, such as source status, active deadline, fit with NCI interests, or partner role.
6 Common Route Mistakes
6 mistakes matter for expired grant pages. That would waste applicant time and damage trust.
Second, users should not treat nanotechnology as fit by itself. The prior route asked for cancer relevance and mechanistic knowledge.
Third, teams should not ignore nanoscale criteria. A material that is small but not engineered for the intended function may not fit.
Fourth, teams should not use this as a clinical route. Clinical trials and human intervention studies were not allowed.
Fifth, users should not skip active-route comparison. Parent R01, NCI assay screening, academic-industrial translation, and SBIR/STTR may be better current choices.
Sixth, a route memo should not simply repeat the expired NOFO. It should map active alternatives, prior award patterns, and route fit for the user's project.
9 Review-Ready Proof Points
9 proof points remain useful even though PAR-25-106 is closed. USASpending.gov data shows about $533.3M in FY2024 obligations for the connected NCI assistance-listing family, so the topic still deserves a useful active-route map. First, the source status should be clear. Second, the cancer problem should be named. Third, the tumor type or pathway should be defined. Fourth, the nanoscale material or device should meet the prior size rule. Fifth, the engineered function should be described. Sixth, the biological mechanism should be testable. Seventh, clinical trials should be excluded. Eighth, active route options should be compared. Ninth, the next source check should be scheduled.
According to NIH, the functional or active component should be at dimensions of 300 nm or less.
The best user outcome is not always a click to the old federal listing. Sometimes it is a move to parent R01, PAR-25-153, PAR-25-338, SBIR/STTR, or a watchlist for a future NCI reissue.
Many people reach PAR-25-106 because the old title still appears in search results, university grant calendars, or saved opportunity lists. The closed status, prior deadline, clinical-trial-not-allowed status, and active-route comparisons are the facts to check first.
A researcher who learns in 60 seconds that PAR-25-106 is closed, then moves to an active NCI or NIH route, has saved weeks of drafting. A researcher who thinks the expired listing is still open can lose that time.
Sources
Current sources anchor this guide: the expired NIH R01 NOFO, NCI cancer nanotechnology program information, active adjacent NCI routes, the federal listing, and the Grantsights public database record.
- NIH PAR-25-106 R01 NOFO: grants.nih.gov (opens in a new tab)
- NCI Cancer Nanotechnology Alliance information: cancer.gov (opens in a new tab)
- NIH PAR-25-153 assay screening route: grants.nih.gov (opens in a new tab)
- NIH PAR-25-336 TTNCI route: grants.nih.gov (opens in a new tab)
- NIH PAR-25-338 academic-industrial translation route: grants.nih.gov (opens in a new tab)
- Grants.gov listing 357274: grants.gov (opens in a new tab)
- Grantsights grant database: Search NCI nanotechnology routes
Next steps
Where to go next
These next pages help you move from research into a specific grant choice.
Open the expired R01 record
Check PAR-25-106 expired status, 300 nm criteria, no-trial scope, and prior fit.
Compare TTNCI
Use when the project is an active preclinical nanotechnology cancer intervention route.
Compare AIP R01
Use when an academic-industrial technology partnership controls the route choice.
Find grants that fit you
Free eligibility check: answer 9 questions and see ranked matches with deadlines and fit reasons.
Frequently Asked Questions
What did PAR-25-106 fund?
NIH says PAR-25-106 supported NCI R01 projects that used nanotechnology to generate mechanistic knowledge for cancer biology, oncology, diagnostics, and therapeutics.
Is PAR-25-106 still open?
No. NIH marks PAR-25-106 as expired, and Grantsights records the deadline as May 4, 2026.
Were clinical trials allowed?
No. PAR-25-106 was clinical trial not allowed.
What nanoscale criteria mattered?
NIH said the functional or active components should be 300 nm or less, and materials should be engineered or modified to provide nanoscale properties or functions.
Who should use this guide?
Use it for route intelligence, prior-cycle fit checks, and comparison with active NCI nanotechnology, cancer tool, and translation routes.
Last updated October 10, 2026. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.
Related Guides
PAR-25-338 academic industrial R01 eligibility Guide
PAR 25 338 academic industrial guide: 7 checks for eligibility, source status, budget, evidence, route fit, and review criteria in 2026.
PAR-24-280 clinical observational R01 eligibility Guide
PAR 24 280 clinical guide: 7 checks for eligibility, source status, budget, evidence, route fit, and review criteria in 2026.
PAR-25-317 family health R01 eligibility Guide
PAR 25 317 family health guide: 7 checks for eligibility, source status, budget, evidence, route fit, review criteria, and next steps in 2026.
PAR-25-112 language development R01 eligibility Guide
PAR 25 112 language development guide: 7 checks for eligibility, source status, budget, evidence, route fit, review criteria, and team readiness in 2026.
PAR-25-379 Native Health R01 Eligibility Guide
NIH PAR-25-379 guide: Native health intervention R01 eligibility, clinical-trial optional fit, community engagement, R01 versus R34, and review checks.
PAR-25-153 NCI Assay Screening R01 Eligibility Guide
NIH PAR-25-153 guide: NCI assay-development and screening R01 eligibility, clinical-trial-not-allowed fit, stages, and review checks.